VJHemOnc Podcast

The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.

In this podcast, you will hear from experts Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, and Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, who discuss key updates in myeloproliferative neoplasms (MPNs) presented at this year's meeting. Topics covered include updates from the MOMENTUM trial (NCT04173494), the importance of combination approaches, and novel agents being explored, including calreticulin (CALR)-targeting antibodies. 

The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.

In this podcast, you will hear from experts Kate Cwynarski, FRCP, FRCPath, PhD, University College Hospitals London NHS Foundation Trust, London, UK, and Swaminathan Iyer, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, who discuss key updates in T-cell lymphoma. Topics covered include the importance of real-world data (RWD) in this space, addressing CNS relapse, and novel treatment approaches being explored.

CD47 is a cell surface protein which is overexpressed in several cancer cells and appears to play an important role in a variety of hematological malignancies, including acute myeloid leukemia (AML), lymphoma, and myelodysplastic syndromes (MDS). Currently, several anti-CD47 agents are under investigation for MDS, with promising results being demonstrated in clinical trials. 

In this exclusive podcast, you will hear from Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, and David Sallman, MD, Moffit Cancer Center, Tampa, FL, who discuss the important role of CD47 in MDS, agents under investigation, and other targets of interest in this space. 

 

The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.

In this podcast, you will hear from Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, and Lindsey Roeker, MD, Memorial Sloan Kettering Cancer Center, New York, NY, who discuss recent updates in chronic lymphocytic leukemia (CLL). The experts comment on the role of doublet and triplet therapies in CLL, clinical trial updates, and further highlight the impact of novel Bruton's tyrosine kinase (BTK) inhibitors in this space.

The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.

In this podcast, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, and Krina Patel, MD, Msc, The University of Texas MD Anderson Cancer Center, Houston, TX, share key updates in multiple myeloma presented at this year’s meeting. The experts comment on real-world experiences with access to CAR-T therapy, the importance of optimizing the sequencing of therapies, ongoing clinical trials in high-risk disease, and more.

The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies. 

In this podcast, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, and Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, discuss key updates in myelodysplastic syndromes (MDS) presented at this year's meeting. Topics covered include the treatment of lower-risk and higher-risk disease, novel classification systems, clinical trial updates, and treatment options after failure to hypomethylating agents (HMAs).

The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Laurie Sehn, MD, BC Cancer Agency, Vancouver, Canada, Carmelo Carlo Stella, MD, PhD, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan Italy, and David Straus, MD, Memorial Sloan Kettering Cancer Center, New York, NY, share some insights into novel therapies in non-Hodgkin lymphoma (NHL), drawing focus on the role of antibody-drug conjugates (ADCs). The experts discuss updates on the use of several ADCs, including brentuximab vedotin, loncastuximab tesirine, polatuzumab vedotin, and camidanlumab tesirine, and where these agents fit in the treatment landscape.

The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, and Carsten Müller-Tidow, MD, University Hospital Heidelberg, Heidelberg, Germany, discuss mechanisms of resistance to targeted therapies in AML, and the role of epigenetics. 

Chronic lymphocytic leukemia (CLL) remains a challenging hematological malignancy to treat, and genomic testing has become increasingly important in this disease. Several genomic tests are commonly carried out prior to initiating treatment, including testing for TP53 aberrations, IgHV mutational status, and more. 

In this podcast, you will hear from Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, Florence Cymbalista, MD, Hôpital Avicenne, Bobigny, France, and Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, who discuss the importance of genomic testing in CLL and how this impacts treatment decisions.

The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Catherine Bollard, MBChB, MD, FRACP, FRCPA, Children's National Health System, Washington, DC, Jeremy Abramson, MD, Massachusetts General Hospital Cancer Center, Boston, MA, Barbara Savoldo, MD, PhD, UNC School of Medicine, Chapel Hill, NC, and Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, discuss the latest updates in T-cell therapies for the treatment of NHL, commenting on real-world data on CD19-directed CAR-Ts, and exploring the potential of other T-cell therapies including CD30, CD20, and CD5-directed CAR-Ts in T-cell lymphomas.